This hypothesis is supported by our findings that a reduced proportion of CCR1-expressing myeloid cells remain in the bone marrow, by the treated versus untreated differential gene expression, by ELISA of bulk tumor lysates, and by the observation that qPCR of tumor cells pointed to CCL9 as differentially produced in combination-treated tumors. The gene discussed is CCR1; the disease is neoplasm.